Phaseline

Targets › CD40

CD40 (Tumor necrosis factor receptor superfamily member 5): drug programs, companies and trials

19 programs from 18 companies in 29 trials: 22 Phase 1, 7 Phase 2; Oncology, Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity). (UniProt, P25942)

Open in Phaseline: the race on CD40, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Roswell Park Cancer InstituteCDX-1140
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 2Ovarian Clear Cell AdenocarcinomaMar 2027
Memorial Sloan Kettering Cancer Center2141-V11 Antibody
CD40 agonist monoclonal antibody
CD40Phase 2Prostate Cancer; Non-muscle Invasive Bladder Cancer; Esophageal CancerNov 2027
National Cancer Institute (NCI)CDX-1140
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 2Head and Neck Squamous Cell Carcinoma; Biliary CancerNov 2027
Veloxis PharmaceuticalsVEL-101
CD40-CD154 pathway antagonist (costimulation blockade)
CD40Phase 2Transplantation, KidneyOct 2028
NovartisIscalimab (CFZ533)
Tumor necrosis factor receptor superfamily member 5 inhibitor
CD40Phase 2Hidradenitis Suppurativa–
RANI TherapeuticsPG-102
Tumor necrosis factor receptor superfamily member 5 inhibitor
CD40Phase 1Obesity; Type 2 Diabetes Mellitus (T2DM)Dec 2026
Providence Health & ServicesCDX-1140
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Malignant Epithelial NeoplasmsDec 2026
University of Southern CaliforniaCDX-1140
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Anatomic Stage IV Breast Cancer AJCC v8Jan 2027
GenmabGEN1042
Bispecific antibody targeting CD40 and 4-1BB (TNFRSF18); DuoBody format
CD40, TNFRSF18Phase 1Malignant Solid TumorJan 2027
Akamis BioNG-350A
Tumour-selective anti-CD40-expressing adenoviral vector
CD40Phase 1Locally Advanced Rectal Cancer (LARC)Jan 2027
AbbVieGiloralimab (ABBV-927)
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Advanced Solid Tumors Cancer; CancerMar 2027
M.D. Anderson Cancer CenterSotigalimab
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Metastatic Colorectal AdenocarcinomaMay 2027
Darell Bigner2141-V11
Anti-CD40 monoclonal antibody
CD40Phase 1Glioma, Malignant; Newly Diagnosed MGMT Unmethylated Glioblastoma; Recurrent Glioblastoma IDH WildtypeJun 2027
AbbVieAzirkitug
CD40 agonist monoclonal antibody
CD40Phase 1Non-Small Cell Lung CancerJul 2027
University of Texas Southwestern Medical CenterCDX-1140
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1HER2-negative Breast CancerApr 2028
XencorPlamotamab
CD40-engaging bispecific antibody
CD40Phase 1Rheumatoid ArthritisJun 2028
University of California, San Diegomitazalimab (CD40 antibody)
CD40 agonist antibody
CD40Phase 1Pancreatic CancerAug 2028
RocheSelicrelumab
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Metastatic Breast CancerSep 2030
Alligator Biosciencemitazalimab
CD40 agonist
CD40Phase 1Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma–

Conditions

Malignant Epithelial Neoplasms (2) Malignant Solid Tumor (2) Glioma, Malignant (1) Newly Diagnosed MGMT Unmethylated Glioblastoma (1) Recurrent Glioblastoma IDH Wildtype (1) Head and Neck Squamous Cell Carcinoma (1) Biliary Cancer (1) Non-Small Cell Lung Cancer (1) HER2-negative Breast Cancer (1) Anatomic Stage IV Breast Cancer AJCC v8 (1) Pancreatic Cancer (1) Advanced Solid Tumors Cancer (1)

Modalities

mixed (9), antibody (5), small molecule (4), protein or peptide (1)

Companies

AbbVie (2) Darell Bigner (1) National Cancer Institute (NCI) (1) University of Texas Southwestern Medical Center (1) University of Southern California (1) University of California, San Diego (1) Providence Health & Services (1) Xencor (1) Genmab (1) RANI Therapeutics (1) Roche (1) Akamis Bio (1) Alligator Bioscience (1) M.D. Anderson Cancer Center (1) Memorial Sloan Kettering Cancer Center (1) Veloxis Pharmaceuticals (1) Roswell Park Cancer Institute (1) Novartis (1)

Related targets

TNFRSF18 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.